SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community discusses the National Oceanic and Atmospheric Administration's (NOAA) determination that its consolidated deep-seabed mining application is in "substantial compliance," marking a significant regulatory milestone for critical mineral extraction. This development, alongside an expanded project area, reinforces bullish sentiment regarding the company's role in securing vital metals for national security and energy independence amid global geopolitical shifts.

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Calamp Corp.

Camp4 Therapeutics is surging after announcing an oversubscribed $100 million private placement to advance its SYNGAP1-related disorder treatment, with the community actively discussing low float dynamics and potential for a significant short squeeze amid heavy trading volume.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment (AVAV) is experiencing high trading volume and volatility following a Raymond James downgrade that cited the U.S. Space Force recompeting its major $1.4 billion SCAR program, leading to a significant price drop. However, many in the community view this as an overreaction, with other analysts reaffirming bullish outlooks and the company confident in renegotiating the crucial drone systems contract amid increasing global demand for its defense technology.

Space and Time is the Microsoft-backed blockchain for ZK-proven data. Powered by Proof of SQL, a sub-second ZK coprocessor, Space and Time allows smart contracts, AI agents, and onchain applications to query onchain and offchain data at scale and verify the results with cryptographic proofs. The foundation of Space and Time is a decentralized layer 1 blockchain where validators verify every piece of data that gets inserted into the network, updating and signing cryptographic commitments on the data before recording them onchain. Developers can query this data via Proof of SQL and receive back a trustless, tamperproof result onchain. Space and Time allows smart contracts to query over the full history of major blockchains and offchain sources in a verifiable way, enabling a new generation of sophisticated, data-driven onchain apps.  The SXT token is deployed as an ERC-20 token on Ethereum and functions as the network's native utility token. SXT is used for staking, data processing payments, access control, and incentives for data contributors.

Space and Time

Space and Time (SXT) is trending due to its core infrastructure role in providing verifiable blockchain data, highlighted by its recent integration with Microsoft Fabric for AI and smart contracts, alongside significant backing from Microsoft, Samsung, and a newly established Grayscale Trust. The community is actively discussing its potential as a foundational Web3 project and noting its recent upward momentum after a period of consolidation.

Literally a dog wif a hat, dogwifhat (WIF) is a meme coin that's part of the ever-growing ecosystem of digital currencies on the Solana blockchain. This token brings a lighthearted twist to cryptocurrency, featuring a playful dog with a hat as its mascot, symbolising a more whimsical approach to the often serious domain of digital finance.

dogwifhat

Dogwifhat (WIF) is facing extreme volatility and polarized community sentiment, driven by recent FUD and rumors of a potential delisting, while many traders debate if current dips represent a significant buying opportunity for the meme coin.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

Upcoming 1-for-5 reverse stock split is driving significant conversation around MSTY, with investors widely concerned about sustained NAV erosion and declining dividend payouts. The community actively debates the fund's long-term viability and its performance, which is closely tied to MicroStrategy and Bitcoin.

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Adlai Nortye Ltd. - ADR

Adlai Nortye Ltd. American

Adlai Nortye Ltd. is a hot topic after securing a $140 million private placement at $6.50 per share with major institutional backing, complementing a recent licensing deal for its pan-RAS inhibitor potentially valued at up to $230 million. The community debates whether the institutional vote of confidence and deal pipeline signal a massive upside or if the current trading levels are overextended given the financing price.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is trending amid significant ecosystem growth, including integrations with prediction market platforms and DEX perpetual futures, alongside rapid increases in Total Value Locked (TVL) and user adoption. The community is actively discussing its attractive staking yields and positioning as a high-performance Layer 1 blockchain, anticipating substantial long-term potential.

XBP Global Holdings, Inc. is a multinational business process automation, which engages in the exchange of bills, payments, and other related digitization services. The firm connects its buyers and suppliers across industries, which include banking, healthcare, insurance, utilities, and the public sector. It operates through the Bills and Payments, and Technology segments. The Bills and Payments segment focuses on optimizing how bills and payments are processed by businesses of all sizes and industries. The Technology segment refers to the sales of recurring software licenses and related maintenance, hardware solutions and related maintenance, and professional services. The company was founded on July 8, 2020 and is headquartered in Irving, TX.

XBP Global Holdings Inc.

XBP Europe Holdings Inc

XBP is trending amid overwhelming community concern and accusations of 'scam' and 'XELA 2.0' following its significant Q3 net loss and high debt, compounded by a recent reverse stock split and ongoing fears of massive dilution.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending with high anticipation for its imminent Phase 3 REGAL trial data readout for AML, driven by community enthusiasm for "curative outcomes," potential for a massive short squeeze, and buyout speculation, despite some investor concerns regarding valuation and trial uncertainties.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

Key Points15,000 shares were sold for a transaction value of approximately $928,950 at a weighted average price of around $61.93 per share on Feb. 5, 2026...

GW&K Investment Management LLC Takes $9.93 Million Position in Cytokinetics, Incorporated $CYTK

GW&K Investment Management LLC purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the...

GABELLI & Co INVESTMENT ADVISERS INC. Makes New $2.06 Million Investment in Cytokinetics, Incorporated $CYTK

GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the third quarter, according to its most recent disclosure...

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 26,000 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 26,000 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $61.87...

Segall Bryant & Hamill LLC Boosts Position in Cytokinetics, Incorporated $CYTK

Segall Bryant & Hamill LLC lifted its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 116.1% during the third quarter, according to the company in its most recent Form 13F...

Royce & Associates LP Invests $5.50 Million in Cytokinetics, Incorporated $CYTK

Royce & Associates LP bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with...

Legato Capital Management LLC Takes Position in Cytokinetics, Incorporated $CYTK

Legato Capital Management LLC acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 3rd quarter, according to its most recent 13F filing with the...

Rafferty Asset Management LLC Has $5.72 Million Holdings in Cytokinetics, Incorporated $CYTK

Rafferty Asset Management LLC trimmed its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 39.3% in the 3rd quarter, according to the company in its most recent Form 13F filing...

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-one analysts that are currently covering the company, Marketbeat...

Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 626.0% during the 3rd quarter, according to the company in its most recent filing...

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CYTK News

CYTKCytokinetics Inc